Palivizumab is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease (bronchopulmonary dysplasia, premature birth, and hemodynamically significant congenital heart disease).

NON-FDA APPROVED USES

  • Treatment of serious RSV pneumonia in immunocompromised adult patients (limited data).

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: November 2, 2015

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Palivizumab ID - 540413 A1 - Pham,Paul,Pharm.D. BCPS Y1 - 2015/11/02/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540413/all/Palivizumab PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -